Scientific Team-GOPATH
diagnostic services Pharma



Sarah Bacus, Ph.D., Director of Pharma Initiatives
 
Dr. Bacus has earned worldwide recognition as a leader in personalized medicine. She has more than 30 years of experience in basic and applied research in oncology drug development and diagnostics.
 
Prior to joining GoPath, Dr. Bacus acted as Senior Vice President and Head of Translational Research for American Molecular Laboratories, which was preceeded by other executive and chief scientific roles at other diagnostics firms. She has also founded and sold four successful companies that were all focused on diagnostic and pre-clinical work for personalized medicine in oncology. These companies revolutionized tissue imaging, accelerated approval of drugs such as lapatinib and helped establish novel treatment strategies in use today. She has noteworthy accomplishments in preclinical drug development, applied and basic oncology research, personalized medicine and development of diagnostics and biomarkers. She has written more than 120 peer reviewed papers and has held multiple worldwide patened biomarkers.
 
Dr. Bacus has held professorships at Duke University and the University of Illinois at Chicago.  She earned a BSc in Physics and Mathematics, M.Sc. in Biophysics and a PhD in Medical Physics at the Hebrew University in Israel.

 
Christopher Hamm, Ph.D., Deputy Director of Pharma Initiatives
 
Dr. Hamm came to GoPath’s PharmaTargetTM team with strong academic credentials and valuable experience in the life sciences/biotechnology sector including human disease studies and therapeutic/drug pipeline/molecular diagnostic/clinical trial analyses. His expertise in the fields of cancer biology, immuno-oncology, molecular biology, cell biology, genetics, genomics, epigenetics and epigenomics gives him valuable insight when creating strategies in drug development.
 
Dr. Hamm is a proven project leader directly involved with the design and execution of basic and translational research projects with the goal of identifying novel therapeutics and companion diagnostics. His direct involvement with biotechnology/pharmaceutical companies includes evaluating products/pipelines, and identifying both key value drivers and undervalued investment opportunities. His doctoral background, combined with ongoing financial training, provides the biomedical expertise and investment knowledge that is directly relevant to modern scientific research (translational and clinical), biotechnology investment research, and strategic management consulting.
 
Prior to joining GoPath, Dr. Hamm acted as the Associate Director of Translational Research for American Molecular Laboratories where he helped develop genomic and proteomic immuno-oncology assays. Dr. Hamm has also acted as a project manager fand clinical genomics scientist for pharmaceutical and clinical research companies. He received his Ph.D. in Genetics from the University of Iowa.